<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41010679</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Cardiovascular Effects of Inflammatory Bowel Disease Therapy with Biologics and Small Molecules: A Comprehensive Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6476</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14186476</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> &#x399;nflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is increasingly associated with cardiovascular (CV) complications, such as heart failure (HF), arrhythmias, and acute coronary syndromes (ACSs). As the therapeutic landscape of IBD evolves, with the introduction of newer biologics and small molecules, their CV safety warrants critical evaluation. The objective of this review is to provide an update on the current evidence of CV risks associated with IBD treatments. <b>Methods:</b> A comprehensive literature search from inception to April 2025 was conducted using PubMed and Medline to identify randomized controlled trials, observational studies, systematic reviews, as well as pharmacovigilance data reporting CV safety outcomes of biologic and small-molecule drugs approved for IBD. Additionally, analysis of the European Summary of Product Characteristics for each agent was also performed. <b>Results:</b> Anti-TNF agents, particularly infliximab, have been associated with increased reporting of HF and arrhythmias, particularly in patients with pre-existing cardiac disease. Ustekinumab and vedolizumab show consistently favorable CV safety profiles across trials and real-world studies. IL-23p19 inhibitors demonstrate low CV event rates overall, although signals for atrial fibrillation have emerged with risankizumab. Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators carry class-specific CV warnings, due to signals mainly on non-IBD populations, and require careful use in high-risk individuals. <b>Conclusions:</b> Although most IBD therapies are generally safe from a CV perspective, certain agents may pose risks in vulnerable patients. Individualized CV risk assessment and ongoing post-marketing surveillance are essential to guide therapeutic choices and ensure patient safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mastoridou</LastName><ForeName>Eleftheria M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0009-0000-3763-4064</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Division of Internal Medicine, Department of Internal Medicine, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fousekis</LastName><ForeName>Fotios S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakellariou</LastName><ForeName>Xenofon M</ForeName><Initials>XM</Initials><Identifier Source="ORCID">0000-0002-1336-0211</Identifier><AffiliationInfo><Affiliation>2nd Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mpakogiannis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikas</LastName><ForeName>Dimitrios N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0002-8333-4879</Identifier><AffiliationInfo><Affiliation>1st Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalis</LastName><ForeName>Lampros K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0001-8834-4462</Identifier><AffiliationInfo><Affiliation>2nd Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsanos</LastName><ForeName>Konstantinos H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milionis</LastName><ForeName>Haralampos</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3958-2266</Identifier><AffiliationInfo><Affiliation>1st Division of Internal Medicine, Department of Internal Medicine, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndromes</Keyword><Keyword MajorTopicYN="N">arrhythmias</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">cardiovascular safety</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">small molecules</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41010679</ArticleId><ArticleId IdType="doi">10.3390/jcm14186476</ArticleId><ArticleId IdType="pii">jcm14186476</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>